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Abstract
Clostridium difficile infection (CDI) is a growing concern with regard to increases in incidence and its associated financial burden. A retro-
spective analysis of patients admitted to Hospitals in Edinburgh from 2003 to 2007 and tested for C. difficile toxins was performed. A
total of 45 412 faecal samples were tested and 6286 (13.8%) were positive. Overall CDI was identified in 1.7 cases/1000 in-patient
occupied bed days (OBD). The incidence of CDI fell from 1.98 cases/1000 OBD in 2006 to 1.48 cases/1000 OBD in 2007. Renal Medi-
cine, including Transplant Surgery, and Intensive Care had the highest incidence, with >6.2 cases/1000 OBD each, followed by Infectious
Diseases and Gastrointestinal Medicine, with rates of 5.5 and 4.42 cases/1000 OBD, respectively. Medicine of the Elderly had an inci-
dence of 1.69 cases/1000 OBD. Incidence increased with age, from 0.45 cases/1000 OBD in the 0–20-year-old age group to 2.02 cases/
1000 OBD in the 61–80-year-old age group. Twelve percent of all toxin-positive patients were transferred through a minimum of two
specialties when they remained positive for C. difficile toxins. Estimated costs over the study period for toxin testing were approximately
£126 500 and the minimal potential hospitalization costs for patients with CDI was £20 000 000. The overall incidence of patients iden-
tified with CDI fell in 2007 compared to 2006. The incidence has increased with age; however, patients in Medicine of the Elderly had a
much lower incidence than in several other specialties and therefore risk assessment of CDI should also be targeted within other spe-
cialties. Judicious application of infection control measures remains important for preventing CDI.
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Introduction
Clostridium difficile infection (CDI) has increased over the past
three decades and is the principal cause of nosocomial
diarrhoea in adults and an important cause of antibiotic-asso-
ciated diarrhoea. CDI covers a spectrum of disease from
asymptomatic carriage, mild self-limiting diarrhoea, through
to severe diarrhoea, pseudomembranous colitis and toxic
megacolon, with the possibility of perforation and death [1].
Very limited information has been published on the bur-
den of CDI to the diagnostic laboratory, and the relative
incidence of disease in different clinical specialties is not well
known. The present study aimed to use locally collected data
from 2003 to 2007 to assess the laboratory workload associ-
ated with C. difficile testing and to analyse the maximal
potential rates of CDI across specialties and age groups, in
an area that had not been affected by the hypervirulent 027/
BI/NAP 1 strain during the period of the study.
Materials and Methods
Setting
Lothian University Hospitals Division provides for approxi-
mately 620 000 people in the Edinburgh area of Southeast
Scotland. The six major Edinburgh hospitals (three tertiary
and three secondary care; totalling approximately 2300 beds)
were included in our analysis.
Laboratory diagnosis of CDI
All faecal samples were processed in a single microbiology
laboratory, in accordance with local guidelines until September
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2006 and thereafter national guidelines [2]. All diarrhoeal
(semi, unformed or liquid) specimens were tested from 2003
to 2008 inclusive if they were from hospital in-patients aged
over 1 year old, if a diagnosis of antibiotic-associated diar-
rhoea or pseudomembranous colitis was present, on clinical
request, or if they had been on recent antibiotic therapy.
Diarrhoeal samples were tested for C. difficile toxins A and B
by enzyme immunoassay (Techlab C. difficile Tox A/B II kit;
TechLab, Blackburg, VA, USA) in accordance with the manu-
facturer’s guidelines.
Inclusion criteria
All in-patients from whom an appropriate faecal sample was
submitted for toxin detection were included. Patients were
identified using the laboratory computer filing system (iLab,
iSOFT, Banbury, UK), which stores details of every sample
tested. The data included patient demographics, ward and
specialty where admitted at the time of sample collection,
date of sample collection, test performed and results.
A new potential CDI episode was defined in line with
Scottish guidelines: ‘only persons that have not been diag-
nosed with Clostridium difficile-associated diarrhoea within the
previous 28 days are counted as new cases’ [3]. Therefore,
any repeat samples taken within 28 days after a positive
result for any individual patient were excluded.
Potential CDI rates were calculated as potential episodes
per 1000 in-patient occupied bed days (OBD) using data,
obtained from the Information Analysis Department, Health
Intelligence Unit, NHS Lothian, on annual hospital occupied
bed days per speciality. Data for renal medicine and trans-
plant surgery had to be combined as a result of the combina-
tion ward set-up.
For all analyses, other than requisition of faecal samples
and the resultant workload relating to individual age groups,
individuals aged less <18 years were excluded because paedi-
atric age groups have been reported to have disproportion-
ately high carriage rates [4,5]. This enabled a comparison
with other studies, which have only included adults. With
recognition that every faecal sample positive for C. difficile
toxin does not always equate to symptomatic CDI, we have
referred to potential CDI.
Costs data
The most recent published data were used to calculate
potential associated costs [6].
Statistical analysis
Analysis was performed using Microsoft Excel (Microsoft
Corp., Redmond, WA, USA) and Minitab, version 5.1.0.0
(Minitab Inc., State College, PA, USA).
Results
A total of 45 412 samples were tested for toxin and 6286
(13.8%) were positive. After excluding repeat positive sam-
ples from the same patient in a 28-day period, 4922 new
potential episodes of CDI were identified, increasing from
875 potential cases in 2004–1231 in 2006 (Table 1). The
overall rate of potential CDI for in-patients admitted from
2003 to 2007 was 1.70 cases/1000 in-patient OBD with a
peak of 1.98 potential cases/1000 OBD in 2006 (Table 1).
The potential number and rate of CDI fell in 2007–928 cases
and 1.48 cases/1000 OBD, respectively.
Laboratory workload
The number of samples tested increased from 6493 in 2003
to 14207 in 2006, falling to 10359 in 2007. The proportion of
these samples identified as positive varied annually from 11%
to 16% (Fig. 1a). There was an almost equal proportion of
samples from Medicine of the Elderly, all medical specialties
and all surgical specialties. The former was the specialty that
sent the maximum number overall, and was almost double
the proportion of samples sent by the next three specialties
individually (General Surgery, Gastrointestinal Medicine and
Infectious Diseases). Medicine of the Elderly had the largest
proportion of positive samples (22.9%) followed by Urology
(17.7%), Renal Medicine/Transplant Surgery (16.8%), Respira-
tory Medicine (15.3%) and General Surgery (14.2%) (Fig. 1b).
Stratifying the data according to age, the largest propor-
tion of samples was sent from the 61–80-year-old age group
and the highest positivity rate was seen in those aged over
80 years. One third of all samples were sent from those
aged 60 years or younger and 18.9% of positive samples
came from this age group (Table 2).
Clinical workload
Renal Medicine/Transplant Surgery with 7.24 cases/1000
OBD and Intensive Care and High Dependency
TABLE 1. Incidence and number of Clostridium difficile infec-
tion (CDI) episodes from 2003 to 2007
Year
Total number of
CDI episodesa
Incidence of CDI
episodes per 1000 OBDb
2003 897 1.93
2004 875 1.51
2005 991 1.65
2006 1231 1.98
2007 928 1.48
aTotal number of episodes of CDI per year (as defined by a stool sample posi-
tive for C. difficile toxin). In the case of multiple positive samples from the same
patient within a 28-day period, only one was included in the total.
bChanges in the incidence of CDI episodes per 1000 occupied bed days (OBD).
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(ITU + HDU) with 6.23 cases/1000 OBD had the highest
potential CDI incidences followed by Infectious Diseases and
Gastrointestinal Medicine, where rates were 5.50 and 4.42
cases/1000 OBD, respectively. By comparison, Medicine of
the Elderly had an incidence of 1.69 cases/1000 OBD. In
addition General Surgery and Urology both had higher rates
than Medicine of the Elderly (Fig. 2a).
On review of the trends in potential CDI incidence in the
seven specialties with the highest rates over the 5-year per-
iod (Fig. 2b), all latterly had a reduction in CDI cases despite
following varying trends. ITU + HDU, Infectious Diseases
and Gastrointestinal Medicine appeared to have the greatest
reduction. For each specialty, the rates peaked at different
times. Renal Medicine/Transplant Surgery had a maximal rate
in 2006, ITU + HDU in 2004, Infectious Diseases and Gas-
trointestinal Medicine in 2005, Urology in 2006, General Sur-
gery in 2003 and Medicine of the Elderly in 2006.
The incidence of potential CDI rates also increased with
age from 0.45 cases/1000 OBD in the 0–20-year-old age
group to 2.02 cases/1000 OBD in the 61–80-year-old age
group. Similar to the specialty trends, there was latterly a
reduction in all age groups. Over the period for those aged
above 41 years, each group appeared to follow a similar
trend, with peaks in incidences in 2003 and 2006. However,
in the younger two age groups, the peak occurred later: in
2005 in the 21–40-year-old age group and in 2006 in the
0–20-year-old age group (Fig. 3).
Of all toxin-positive patients, 12% were transferred
through a minimum of two specialties and 17% of these
through a minimum of three to a maximum of six specialties.
These transfers also included movement through acute-
service areas: Accident and Emergency, Combined Assess-
ment Units and Acute Receiving Units.
Discussion
The C. difficile-related burden handled by the laboratory and
the potential clinical workload over a 5-year period within
Edinburgh were assessed. The results represent the first
study from Scotland, and possibly the first ever, demonstrat-
ing the CDI laboratory workload. The recent CDI trends
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FIG. 1. Trends in number of laboratory requests for Clostridium diffi-
cile toxin detection 2003–2007. (a) Total number of laboratory
requests for C. difficile toxin detection per year. The figures above
the individual bars represent the percentage of positive samples per
year. (b) Total number of laboratory requests for C. difficile toxin
detection distributed by specialty. Shaded areas: positive results for
C. difficile toxin; nonshaded areas: negative results for C. difficile toxin.
The figures above the individual bars represent the percentage of
samples that were positive per specialty. HAEM-ONC, Haematology
and Oncology; INF-DIS, Infectious Diseases, ITU/HDU, Intensive
Care and High Dependency Units; MED, General Medicine;
MED-CARDIO, Cardiology; MOE, Medicine of the Elderly; MED-GI,
Gastrointestinal Medicine; MED-OTHER, includes all other medical
specialties including dermatology and rheumatology; MED-RESP,
Respiratory Medicine; OBS-GYN, Obstetrics and Gynaecology;
RENAL MED, Renal Medicine and Transplant Surgery; SURG-CT,
Cardiothoracic Surgery; SURG-GEN, General Surgery; SURG-ORTH,
Trauma and Orthopaedic Surgery; SURG-OTHER, includes all other
surgical specialties including vascular; SURG-URO, Urology;
UNKNOWN, Samples that could not be allocated to a particular
specialty.
TABLE 2. Number of samples tested (total and proportion
positive) by the laboratory, distributed according to age
group
Number of samples (%)
Age
range Tested Positive
Percent positivity
per age group (%)
0–20 1973 (4.3) 94 (1.5) 4.8
21–40 4588 (10.1) 293 (4.7) 6.4
41–60 8697 (19.2) 800 (12.7) 9.2
61–80 18211 (40.1) 2772 (44.1) 15.2
>80 11943 (26.3) 2327 (37.0) 19.5
Total 45412 (100) 6286 (100) 5.9
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and maximal potential specialty-dependent rates are also
reported. Although the study reviews presumptive rates of
specialty-based CDI based on toxin-positive samples rather
than symptomatic disease, it provides valuable information
on the burden of disease prior to mandatory data reporting,
introduced in September 2006, and for age groups below
65 years.
A fall in the rate of CDI occurred between to 2003–2004
and 2006–2007. The initial reduction may be secondary to
increased awareness and improved infection control prac-
tices with the subsequent rise occurring if infection control
measures relaxed with an associated increase in antibiotic
usage (e.g. of fluoroquinolones). The decline seen latterly
may represent enhanced infection control measures including
improvements in CDI-related education and judicious antibi-
otic use.
This is converse to some other reported figures. In Can-
ada, an increase in incidence from 2.5 cases/1000 admissions
to 4.6 cases/1000 admissions occurred from 2002 to 2007
[7]. In Spain, where ribotype 027 is not prevalent, the preva-
lence rates have increased from 0.39 to 1.22 cases/1000 hos-
pitalized patients from 1999 to 2007 [8]. The incidence of
1.27 CDI cases/1000 OBD in the whole of Scotland from
October 2006 to September 2007 for those aged 65 years
and over [4] was lower than the 1.99 CDI cases/1000 OBD,
for the same period and cohort of patients, in the present
study. This may be a result of our study representing poten-
tial CDI in a concentrated urban population.
There was a 54% increase in the number of samples analy-
sed by the laboratory from 2003 to 2006. Although the num-
ber decreased from 2006 to 2007, there was a 37% increase
from 2003 to 2007. This will have impacted upon staff as
well as upon an appropriate analysis of samples, timely data
reporting, storage of samples and further testing of repeat
samples from previously positive patients.
This increase will also have had implications for ward-
based staff with regard to rapid and appropriate patient isola-
tion, cleaning procedures and continued patient management.
One-third of samples were from those aged 60 years and
under, and this population also accounted for approximately
one-fifth of the total positives (Table 2).
This was similar to results from the recent 2009 European
Study (M. Bauer, unpublished data) where 37% of samples
were submitted from those aged 65 years or under. In the
Netherlands in 2005, 42% of samples were submitted from
this age group [9]. In the present study, CDI toxin positivity
was identified in all age groups, including that aged
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FIG. 2. Distribution of Clostridium difficile infection (CDI) incidence
among the various specialties from 2003 to 2007. (a) Annual
incidence of CDI in the seven specialties with the highest overall
incidence of CDI [episodes per 1000 occupied bed days (OBD)].
(b) The overall incidence of CDI episodes per 1000 OBD per spe-
cialty. HAEM-ONC, Haematology and Oncology; INF-DIS, Infectious
Diseases, ITU/HDU, Intensive Care and High Dependency Units;
MED, General Medicine; MED-CARDIO, Cardiology; MOE, Medicine
of the Elderly; MED-GI, Gastrointestinal Medicine; MED-OTHER,
includes all other medical specialties including dermatology and rheu-
matology; MED-RESP, Respiratory Medicine; OBS-GYN, Obstetrics
and Gynaecology; RENAL MED, Renal Medicine and Transplant
Surgery; SURG-CT, Cardiothoracic Surgery; SURG-GEN, General
Surgery; SURG-ORTH, Trauma and Orthopaedic Surgery; SURG-
OTHER, includes all other surgical specialties including vascular,
SURG-URO, Urology.
0
0.5
1
1.5
2
2.5
3
2003 2004 2005 2006 2007
CD
I e
pi
so
de
s/
10
00
 O
BD
0–20
21–40
41–60
61–80
>80
FIG. 3. Distribution of annual age-related Clostridium difficile infection
(CDI) incidence [episodes per 1000 occupied bed days (OBD)] from
2003 to 2007.
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0–20 years, and the potential CDI incidence in those aged
21–40 and 41–60 years was not largely dissimilar from that
in those aged over 60 years. It should be noted that the
potential false positive rates will be higher among the younger
age groups because the potential prevalence in these age
groups (aged 60 years and under) is <10%. With mandatory
data reporting in Scotland initially introduced for those aged
65 years and above only, a large and important subset of
patients was excluded from national figures. Subsequent to
May 2009, mandatory data reporting in Scotland will now
include those aged 16 years and above.
The elderly population is deemed to be at high risk for
CDI; however, it is no longer the only at-risk group [10]. An
analysis of our data by specialties revealed that Obstetrics
and Gynaecology patients, a group with minimal CDI, have a
low but noteworthy incidence of disease. Because there are
only a few reports of peripartum CDI in young women [11],
they, along with paediatric patients, comprise a sub-group
where there should be vigilance and a high degree of clinical
suspicion in symptomatic patients.
Advanced age has been found to be an independent pre-
dictor of mortality in patients with CDI [12]. However, in
the present study, Medicine of the Elderly had a much lower
incidence than several other specialties, although it
accounted for the largest number of samples tested and had
the greatest proportion of positive samples. Renal Medicine/
Transplant Surgery, ITU, Infectious Diseases, Gastrointestinal
Medicine, Urology and General Surgery all had a higher inci-
dence of CDI.
This is similar to a study from Amsterdam where CDI
occurred more frequently in ITU patients and those admit-
ted to surgery [13]. Conversely, in Spain, admission to a
general medical ward was associated with higher CDI pre-
valence as opposed to ITU admission [8].
Renal Medicine/Transplant Surgery had the highest inci-
dence of CDI over the study period. This may reflect over-
all antibiotic usage, immunosuppression and repeated
admissions. Chronic haemodialysis patients have a greater
risk of developing nosocomial infections including CDI
[14] and renal insufficiency is associated with increased
risk of CDI after live donor liver transplantation [15]. Liver
disease is also independently associated with severe CDI
outcome [7].
The recognition of patients with severe CDI, subsequent
to outbreaks in Canada [16] and Stoke Mandeville (Bucks,
UK) [17], could have resulted in an increased number of
patients with CDI being referred to ITU and hence the
observed peak in 2004. The marked decline in potential CDI
incidence observed afterwards within ITU and HDU areas
may be a result of increased awareness, stringent infection
control and the overall decrease seen across all specialties.
In the present study, the incidence of CDI among
ITU + HDU patients was 6.23 cases/1000 OBD.
Lawrence et al. [18] reported an incidence of CDI in ITU
to be 3.2 cases/1000 patient days in the absence of an out-
break. This may be a result of differences in patient popula-
tions and our figure represents a maximal potential
incidence, which includes patients transferred to ITU with
CDI. In 2008, a study reported that a specific subgroup of
young critically ill trauma patients admitted to ITU developed
CDI even though administration of antibiotics was for surgi-
cal prophylaxis only [19].
Gastrointestinal Medicine may handle a substantial burden
of CDI as a result of a high prevalence among inflammatory
bowel disease patients. CDI has been reported to be eight-
fold more prevalent in patients with ulcerative colitis and
five-fold more prevalent in patients with Crohn’s disease
compared to the general population [20,21].
General Surgery had a plateau from 2003 to 2006 despite
a rise in the total CDI incidence in 2006. This contrasts to
other studies that noted a rise in CDI among patients admit-
ted in surgery, particularly for patients requiring surgical
intervention for CDI [22–24]. Although patients are at risk
of acquiring CDI within the specialty itself, patients are also
referred for surgical intervention due to severe fulminant
C. difficile colitis and typhlitis. This may suggest that patients
were not being referred for surgical review; disease severity
did not warrant surgery or patients were not suitable for it.
Early surgical referral should always be made for severe ful-
minant colitis as a total colectomy prior to acute respiratory
or renal failure in those aged over 65 years is associated
with decreased mortality [22].
The incidence of CDI in Urology did not vary greatly and
the overall incidence was 1.84 cases/1000 OBD. This was
higher than observed by Hossain et al. [25] who reported an
incidence of 0.66 cases/1000 OBD.
Approximately one-tenth of all toxin-positive patients
were transferred through a minimum of two specialties when
remaining toxin positive. The maximum number of inter-spe-
cialty transfers (and therefore wards) for an individual patient
was six. This does not take into account the number of indi-
vidual bed moves within the same ward. C. difficile spores
contaminate the hospital environment and are more likely to
be recovered from a room housing a CDI patient [26] and
this can persist for up 40 days after discharge [27,28]. Acqui-
sition of CDI is more rapid, occurring after 3.2 days for
patients sharing a room with a CDI patient compared to
18.9 days for those who do not have close contact [29].
Estimated costs for toxin testing alone were approxi-
mately £126 500 (€143 000). On the basis of the most
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recent published European costs of CDI by Vonberg et al.
[6], the excess costs per in-patient case was €7147. This
agrees with the only published figures available for Great
Britain from Wilcox et al. [30] in 1996, where extra costs
were estimated at £4000 (€4500) per case. Without adjust-
ing for inflation, the potential excess costs for CDI patients
over the study period was £20 000 000 (€22 500 000).
Most local strains of C. difficile associated with CDI belong
to ribotypes 001 and 106 [31]. Ribotype 027, and now 078
[32], is associated with increasing CDI rates and more
severe disease.
The incidence of CDI appears similar to regions where
027 was prevalent. Control of CDI should not be focused
solely on 027 and strategies to reduce CDI should consider
the pathogenic potential of local strains. However, the
absence of hypervirulent types may explain the plateau in the
incidence observed in General Surgery.
The present study has confirmed that CDI incidence
increases with age but varies among specialties, indicating
where an assessment of the risk of developing CDI should
be targeted.
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